Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMPV Y high dose vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
hMPV Y high dose vaccine is an investigational human metapneumovirus (hMPV) vaccine candidate developed by GSK. It is a recombinant protein subunit vaccine designed to elicit an immune response against the hMPV fusion (F) protein, which is critical for viral entry into host cells. The vaccine was evaluated in a Phase 1/2 clinical trial (NCT04144712) as part of a dose-finding study in younger and older adults. In this trial, the "Y" designation refers to a specific investigational formulation or construct of the hMPV antigen, and "high dose" indicates the highest concentration level tested in the study. The program aims to prevent respiratory tract infections caused by hMPV, a significant pathogen in pediatric, elderly, and immunocompromised populations.
- Other names
- hMPV Y high dose vaccineGSK investigational hMPV vaccine
02
Targets
HMPV F (Human metapneumovirus fusion protein)
Beyond the preview
Go deeper on hMPV Y high dose vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMPV Y high dose vaccine.